Business
Lynparza positive in metastatic BRCA breast cancer
Lynparza positive in metastatic BRCA breast cancer.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 1622X AstraZeneca PLC 17 February 2017 \n\nThis announcement contains inside information\n \n17 February 2017, 07:00 GMT\n \nLYNPARZA MEETS PRIMARY ENDPOINT IN PHASE III\nTRIAL IN BRCA-MUTATED METASTATIC BREAST CANCER\n \n \nLynparza provided a statistically-significant improvement in progression-free survival compared to chemotherapy\n \nFirst positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer\n \n \nAstraZeneca today announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician's choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations. Patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin).\n \nSean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: \"These results are positive news for patients with BRCA-mutated metastatic breast cancer, a disease with a high unmet need, and are the first positive Phase III data for a PARP inhibitor beyond ovarian cancer. This is highly encouraging for the development of our broad portfolio which aims to treat multiple cancers by targeting DNA damage response pathways.\"\n \nInitial findings from the OLYMPIAD study indicate that the safety profile of Lynparza was consistent with previous studies. \n \nA full evaluation of the OLYMPIAD data is ongoing and the results will be submitted for presentation at a forthcoming medical meeting. AstraZeneca will be working with regulatory authorities to make Lynparza available to patients with this type of breast cancer.\n \nAbout Metastatic Breast Cancer\nApproximately one in eight women are diagnosed with breast cancer. Of these patients, approximately one-third are either diagnosed with or progress to the metastatic stage of the disease.[i] Despite treatment options increasing during the past three decades there is currently no cure for patients diagnosed with metastatic breast cancer. Thus, the primary aim of ...